Non-small cell lung cancer (NSCLC) accounts for more than 85% of incidences of lung cancers. Even with the great advances in immunotherapy in recent years, the response rate to immune checkpoint inhibitor therapy for NSCLC, such as anti-PD1/PDL1 therapy, is only about 20%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.